RGEN Repligen Corporation

NASDAQ
$184.17

Repligen Corporation (RGEN) is confirmed to report earnings on October 27, 2026, before the market open. The consensus earnings estimate is $0.46 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +31.8% since its last earnings release on July 28, 2026.

Repligen Beat Consensus Estimates, Raises Guidance
Tuesday, July 28, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 27
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs $0.46
Rev est $206.64M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $171.89

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.